Biotech investing can feel like a high-stakes sprint—until you realize the real race is often won (or lost) long before the first clinical readout.
Here’s the uncomfortable truth: you can be right on the science and still get burned on the IP.
If you’r…

Biosimilar entry windows aren’t just math—they’re strategy. Here are 5 costly modeling mistakes companies keep making.
In biosimilars, the “entry window” is often treated like a spreadsheet problem: plug in the dates, apply the rules, and move on. But …

Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the “go/no-go” decision is often framed as a technical question: Can we make it? Can we prove it? Can we hit the right endpoints?
But the real inflection p…

Designing Around the Moat: How Generic Developers Can Think About Secondary Formulation Patents
In generic drug development, the “moat” is rarely just the primary patent. It’s often the secondary layer—formulation tweaks, process changes, stability imp…

The Potential Risks of Combining Vascepa with Blood Thinners: What You Need to Know As the medical community continues to… https://www.Drugchatter.com/chat/17808/are-there-any-potential-side-effects-of-combining-vascepa-with-blood-thinners/

Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…

Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…